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1.0 Introduction 
This report was prepared in response to a request from the Nuclear Energy Research Advisory 
Committee (NERAC) subcommittee on "Long-Term Isotope Research and Production Plans." The 
NERAC subcommittee has asked for a reply to a number of questions regarding (1) "How well does the 
Department of Energy (DOE) infrastructure s m e  the need for commercial and medical isotopes?" and 
(2) "What should be the long-term role of the federal government in providing commercial and medical 
isotopes?' 
Our report addresses the questions raised by the NERAC subcommittee, and especially the 10 issues 
that were raised under the first of the above questions (see Appendix). These issues are related to the 
isotope products offered by the DOE Isotope Production Sites, the capabilities and condition of the 
facilities used to produce these products, the management of the isotope production programs at DOE 
laboratories, and the customer service record of the DOE Isotope Production sites. 
An important component of our report is a description of the Fast Flux Test Facility (FFI'F) reactor at 
the Hbford Site and the future plans for its utilization as a source of radioisotopes needed by nuclear 
medicine physicians, by researchers, and by customers in the commercial sector. 
In response to the second question raised by the NERAC subcommittee, it is our firm belief that the 
supply of isotopes provided by DOE for medical, industrial, and research applications must be 
strengthened in the near future. Many of the radioisotopes currently used for medical diagnosis and 
therapy of cancer and other diseases are imported from Canada, Europe, and Asia. This situation places 
the control of isotope availability, quality, and pricing in the hands of non-U.S. suppliers. It is our 
opinion that the needs of the U.S. customers for isotopes and isotope products are not being adequately 
served, and that the DOE infrastructure and facilities devoted to the supply of these products must be 
improved This perception forms one of the fundamental bases for our proposal that the FFI'F, which is 
currently in a standby condition, be reactivated to supply nuclear services and products such as 
radioisotopes needed by the U.S. medical, industrial, and research communities. 
2.0 Radioisotope Production at the Hanford Site 
2.1 History of Isotope Production Activities at the Hanford Site 
The Hanford Site, under management of the Westinghouse Hanford Company (WHC), began isotope 
production at the FFl-'F in the 1980s. More than 40 radioisotopes of interest to medical and commercial 
clients were produced In many cases, only trace quantities of isotopes, suitable for research applications, 
were produced However, several isotopes, such as gadolinium- 153 and cadmium- 109, were produced in 
larger quantities and sold for medical applications. All of the radiochemical processing of isotope targets 
irradiated at FFlT was performed in the radiochemistry laboratories of the Pacific Northwest National 
Laboratory (PNNL). In 1991, at the request of DOE, the Hanford Site began weekly production of 
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yttrium-90, which was in the early stages of clinical testing for the treatment of Hodgkin's lymphoma 
using a radiolabeled antibody method PNNL scientists developed a process that was patented in 1996 for 
the production of ultrapure yttrium-90 fiom strontium-90 that was retrieved from nuclear waste .stockpiles 
at Hanford (U.S. patent no. 5,512,256, awarded April 30, 1996). 
In 1996 WHC transferred the'management of the DOE-supported radioisotopes program to PNNL. 
Under PNNL the program was expanded to include research on the production and applications for cancer 
therapy of alpha-emitting isotopes such as radium-223 and actinium-225 and the bismuth-21 3 isotope 
obtained by decay of actinium-225. In addition, through active marketing conducted in collaboration with 
DOE-HQ staff, the medical use of yttrium-90 and worldwide sales of this isotope have rapidly increased 
during the past three years. In part because of its successful management of the medical isotopes program 
at the Hanford Site, PNNL was requested by the Secretary of Energy in May 1999 to lead the develop- 
ment of a scoping plan for the future missions of the FFTF, an important component of which is the 
production of radioisotopes to fill the needs of medical and commercial users. 
2.2 Current Program Activities Sponsored by the Department of Energy 
2.2.1 Isotope Production Activities 
The primary medical isotope produced and sold by PNNL under the sponsorship of the DOE Office 
of Nuclear Energy, Science and Technology's Isotope Programs Office (DOEME-70) has been 
yttrium-90. Largely because of successful clinical trials in the U.S. and Europe and the consistent weekly 
supply of high-purity yttrium-90 supplied by PNNL, the sales of this isotope increased rapidly from 
FY 1996 to FY 1998. The 14-fold increase in sales of this isotope over a two-year period is illustrated in 
Figure 1. 
The rapid increase in yttrium-90 sales led to a successful effort to commercialize the production, 
marketing, sales, and distribution of this isotope product during the past year (described in Section 2.2.2). 
A second area in which research and development activities have been focused during the past three 
years is the development of efficient separation chemistries for alpha emitters of interest in cancer 
therapy. The following specific noteworthy accomplishments in alpha-emitter research have been 
supported primarily by DOEJNE-70: 
1. new processes for separating and purifying thorium-229, actinium-225, and radium-223 from a 
mixture of radionuclides were developed, and a U.S. patent was awarded in September 1998 
(No. 5,809,394) 
2. a new and highly efficient anion exchange procedure was developed to isolate bismuth-213 fiom its 
actinium-225 parent, and a U.S. patent was awarded in May 1998 (No. 5,749,042) 
3. an automated, computer-controlled generator technique was developed at PNNL, and subsequently 
demonstrated to achieve an efficient separation of bismuth-213 while allowing complete recovery of 
the actinium-225 parent species; a U.S. patent application for this technology was filed in 1998 
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Figure 1. Annual Sales of Yttrium-90 Produced at the Hanford Site Since FY 1991 
4. advances were made in developing chelation and linker chemistry for actinium-225 and radium-223 
in collaborative work with scientists from the University of Idaho and the University of Washmgton; 
two U.S. patent applications were filed in 1998 for new chelating agents of the calixarene and crown 
ether families that selectively bind actinium-225 and radium-223. [This work was initiated with 
support from Laboratory-Directed Research and Development (LDRD) funds, and subsequently 
funded by DOEJNE-70.1 
Other research activities with radioisotope products have focused on developing methods for 
delivering isotopes and radiopharmaceutical products to disease sites. An example of ongoing research 
supported by the DOE Office of Biological and Environmental Research involves the use of a radioactive 
polymeh composite for administering high-dose brachytherapy to tumors of the prostate gland and other 
tissues. In this procedure, a direct injection into the tumor mass is made of an isotope solution contained 
in a polymer material that is a fluid at room temperature, but quickly gels at body temperature and retains 
the isotope within the tumor region. A U.S. patent application on this procedure was filed in 1998. 
With the completion of commercialization of the yttrium-90 production program, PNNL will not 
continue to serve as a DOEINE-70 isotope production site in FY 2000. However, special projects 
related to retrieval of medical isotopes such as thorium-228 from stored nuclear stockpiles will be carried 
out on request. 
2.2.2 Commercialization and LeasingILicensing of Isotope Products 
During FY 1998, a Request for Proposal (RFP) was issued by DOE to commercialize the production, 
marketing, sales, and distribution of yttrium-90. The proposals submitted were evaluated by a joint 
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DOEiPNNL team to select a short list of companies whose proposals were considered acceptable. 
Negotiations began in mid-1998, and on October 22, 1998, an agreement to lease 40 curies of highly 
purified strontium-90 for a period of five years was signed by DOE and NEN Life Science Products, Inc. 
A separate license agreement to use PNNL's patented process for extracting yttrium-90 from its 
strontium-90 parent was signed by NEN on October 12,1998. 
Under the lease agreement, DOE receives an immediate fee of $25K and subsequent lease payments 
based on a percentage of the net sales value of yttrium-90 sold by NEN. The estimated value of this lease 
agreement for DOE is approximately $lM over a five-year period based on the current yttrium-90 annual 
sales. Under the license agreement, the management contractor organization for PNNL - the Battelle 
Memorial Institute - receives an initial fee of $75K and subsequent royalties based on a percentage of the 
net sales value of Y-90 sold by NEN. The estimated value of this agreement for Battelle is approximately 
$500K over a five-year license period. 
The lease agreement between DOE and NEN allowed a period of six months for transitioning the 
yttrium-90 production operations from PNNL to NEN laboratories in Billerica, MA. At the beginning of 
May, 1999, NEN began prhcing and selling yttrium-90 to commercial customers. PNNL continued to 
produce yttrium-90 for medical customers involved in Phase 3 clinical trials until early June 1999, in 
order to allow adequate time for the Food & Drug Administration to review and approve NEN's Drug 
Master File and to certify NEN's yttrium-90 product as being of suitable quality for use in advanced 
Phase 3 clinical trials. 
Based on the success of the yttrium-90 commercialization activity, PNNL is currently involved in 
efforts to commercialize other technology that has been developed for the medical application of 
radioisotopes. For example, negotiations are underway with a private company for use of PNNL's 
radioactive composite polymer delivery system for treating prostate tumors and other forms of cancer. 
2.3 Future Plans for Isotope Production at the Hanford Fast Flux 
Test Facility 
2.3.1 Background information on the FFTF 
The FFTF's original mission was to support liquid metal reactor technology development and reactor 
safety by providing fuels and materials irradiation services. Although the U.S. liquid metal reactor 
program ended at about the same time that the FFW commenced operation in 1982, the reactor continued 
operation for 10 years as a national research facility to test advanced nuclear fuels and materials, nuclear 
power plant operating pr&es, and active and passive reactor safety technologies. The facility was 
also used to produce more than 40 different radioisotopes for use in research, medicine, and industry. 
In addition, FFI'F generated tritium for the U.S. fusion research program and supparted cooperative, 
international nuclear research activities. The reactor was shut down in December 1993, and since that 
time has been in a standby operational condition, pending a decision by DOE on its future use. In May 
1999, the Secretary of Energy announced that a special 90-day study led by the Director of the Pacific 
Northwest National Laboratory, Dr. William Madia, would be conducted to establish whethea the JFl'F 
should be considered for future missions related to national and intemational nuclear technology needs. 
This scoping plan for future FFTF missions will be reviewed by NERAC before submission to the 
Secretary of Energy on August 2, 1999. 
k", d' 
2.3.2 Proposed Future Missions of the FFTF 
Because the FFTF has a large target volume and can provide a high flux of neutrons at energies 
ranging from thermal to > 1 MeV, the facility is suitable for a wide variety of nuclear science and 
irradiation services missions. As part of the ongoing development of an FFTF scoping plan, these 
potential missions are being closely evaluated at the time this report is being prepared. The nuclear 
science and irradiation services provided by FFTF will focus on a core federal role of meeting multiple 
21" century needs, including: 
providing a large and reliable supply of radioisotopes for research, medical, and industrial 
applications 
promoting safer nuclear technology through reactor safety testing and the development of 
proliferation-resistant nuclear fuels 
producing power sources for deep-space exploration through the production of plutonium-238 for 
radioisotope thermoelectric generators (RTGs) and research on compact space reactor technology 
sustaining the nuclear option for power production through testing of fuels, components, and reactor 
instrumentation 
u 
conducting advanced research and providing services related to the testing of materials for fusion 
reactors, hardening and testing of materials such as semiconductors, and research on transmutation of 
nuclear waste materials. 
With the establishment of a long-term, stable core federal mission, FFTF would also offer valuable 
options for private sector users. A significant involvement of commercial, academic, and international 
users in the future plans for FFTF is realistic, since the reactor previously demonstrated its ability to 
support multiple users and still achieve a high capacity factor during its ten years of successful operation. 
2.3.3 Capability of the FFTF for Isotope Production 
The FFTF offers several special production advantages relative to other DOE or commercial reactors 
that are currently in operation in the United States: 
1. Neutron Energy Moderation. The FFIF neutron energy spectrum peaks at -300 keV, which 
provides a significant advantage for the production of several medical isotopes that require a high flux 
of fast and high-energy neutrons. An example is the production of copper-67 by an (n,p) reaction 
with a zinc-67 target. Through the introduction of energy moderators such as hydrides, the neutron 
energy spectrum within each target assembly can be moderated over a broad range of energies to 
provide a high flux of fast or epithermal neutrons. In this manner, the neutron energy at each target 
location can be tailored to achieve a maximum reaction rate for producing a specific isotope product. 
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2.3.4 Candidate Medical Isotopes to be Produced at FFTF and Comparison with Market 
Demand and Other DOE Reactor Capabilities 
In planning for a future isotope production mission at FFTF, consideration has been given to the 
projected future demand for a broad range of radioisotopes required for medical and commercial 
applications. The present and future availability of these isotopes from domestic sources has been 
analyzed, as well as the FFTF's capability to supplement the supply of these isotopes to meet the 
projected future demand. From these analyses, together with recent forecasts of the medical isotopes 
market such as those conducted by Frost and sullivanl and the Medical University of South ~a ro l ina ,~  it 
is apparent that the greatest challenge in meeting the market requirements over the coming two decades 
will be in the area of therapeutic medical isotopes. A focus of the planning activities for the future FFTF 
radioisotope production mission has therefore been placed on these isotopes, several of which are 
currently unavailable, or available only in limited quantities, from sources in the U.S. and worldwide. 
For initial planning purposes, a set of 30 medical isotopes was selected on the basis of information 
obtained from several sources, including (1) the above-mentioned medical market forecasts, (2) reviews 
of the medical literature and the - 120 ongoing clinical trials that utilize radioisotopes for the treatment of 
cancer and other diseases, and (3) the report of an expert panel that was formed by DOE in 1998 to assess 
the future demand for medical i~otopes.~ These 30 isotopes are listed in Table 1, along with a description 
of their medical applications. These applications primarily involve the diagnosis and treatment of three 
major classes of disease - cancer, vascular disease (arterial restenosis), and arthritis. Some of these 
isotopes have both diagnostic and therapeutic applications (e.g., iodine-131). It should also be noted that 
several of the isotopes serve as "generators" for other therapeutic medical isotopes that are obtained as 
decay products [e.g., tungsten-1 88 for rhenium- 188, thorium-229 for actinium-225 (and bismuth-21 3), ?---. 
thorium-228 for bismuth-212, and actinium-227 for radium-2231. Table 1 also presents the reaction 
process used to transmute the target isotope through neutron irradiation to make the desired medical 
isotope product. Three types of reaction processes are considered, namely, the capture of a neutron with 
ejection of either a gamma ray or a proton, and inelastic excitation which transforms the target isotope 
nucleus to an excited isomeric state. 
From an analysis of the production requirements for these 30 reactor-generated isotopes, it becomes 
quickly evident that several of them have small ( 4  barn) production cross-sections and require target 
irradiation with fast or high-energy neutrons. The cross-sections and neutron energy requirements for the 
30 isotopes listed in Table 1 are depicted schematically in Figure 4. It is apparent from this representation 
of the isotope production requirements that the FFTF, because of its high flux of fast neutrons and the 
ability to perform flux tailoring using hydride energy moderation, is ideally suited for the efficient 
production of a majority of the medical isotopes listed in Table 1. 
1 
"FFTF Medical Isotopes Market Study (2001-2020)," Frost and Sullivan, Inc., Mountain View, 
California; Pacific Northwest National Laboratory report PNNL-11774, Richland, Washington (1997). 
"Evaluation of Medical Radionuclide Production with the Accelerator Production of Tritium (APT) 
Facility," Medical University of South Carolina report (July 15, 1997). 
Expert Panel Report: "Forecast Future Demand for Medical Isotopes," DOE Cooperative Program 
Project #130, final report (April 1 998). 
8 
Table 1. Thirty Candidate Medical Isotopes for Production at FFTF 
interstitial radiation therapy, brachytherapy for treatment of 
immunotherapy, imaging, cellular dosimetry, adrenal medulla 
scintigraphy, treatment of Grave's disease, treatment of goiters, 
treatment of prostate cancer, treatment of hepatocellular 
carcinoma, treatment of melanoma, locate metastatic lesions, 
treatment of neuroblastoma and malignant pheochromocytoma, 
internal (systemic) radiation therapy, treatment of thyroid 
Table 1. (Contd) 

Table 2. FFTF Production Advantages for Medical Isotopes 
thermal neutrons. 
b) Cross-sections (resonance integrals) characterized as S (small, c5 barns), M 
(medium, 5 - 500 barns), and L (large, >500 barns). 
For purposes of calculating the FFI'F production rates of the 30 isotopes listed in Table 1, a 
representative core map for FFI'F operations in a future multiprogram mission has been developed. The 
important features of this core configuration for medical isotope production are: 
One assembly located in Row 4 and two assemblies in Row 6 are available for production of short- 
lived isotopes (tin 5 2 weeks) that require the removal of targets using a rapid radioisotope retrieval 
(R3) system while the reactor is at full power. 
A continuous-flow gas line is available in Row 2 for the production of products such as iodine-1 25 
(from a xenon-1 24 gas target). 
A total of 3 to 12 positions for the production of longer-lived isotope products are available in Row 6 
of the core region; these products would be produced using a long-term irradiation vehicle (LIV) for 
the targets, which would be removed only at the end of an operating cycle when the reactor power is 
reduced for scheduled maintenance procedures. A preliminary analysis indicated that at least 9, and 
possibly 12, LNs  in Row 6 could be used for medical isotope production without significantly 
impacting other FFTF irradiation services. 
In the current model of the FFIF core configuration, 48 LIV assemblies in Row 9 (the outamost row 
of the reflector region) can be dedicated to the production of cobalt-60 for sale to companies that 
manufacture stailization equipment and medical teletherapy units. Based on the calculated cobalt-60 
production yield for three 100-day FFTF operating cycles, - 4 million curies of this isotope can be 
produced annually. 
Although the FFTF has a rated power of 400 MW, initial operations in the proposed future 
multiprogram mission will be conducted at a power level of 100 MW. This choice of power level will 
permit the use of existing reactor fuel supplies for at least five years, and will extend the reactor's lifetime 
well beyond the current estimate of 22 years for operation at a 400-MW power level. Accordingly, 
estimates of medical isotope production rates presented in this report are for FFTF operations at 100 MW 
Table 3 presents a summary of the calculated rates of production in FFTF of the 30 medical isotopes 
listed in Table 1. These calculations were made for irradiation cycles ranging from 10 days for the 
shortest lived isotope species to 100 days for the longer-lived isotopes. It is assumed that the typical 
FFTF operating cycle between schbled maintenance pr-es will be approximately 100 days. The 
target masses shown in Table 3 were selected on the basis of available volume in the R3 irradiation 
vehicles used for short-lived isotope products, and also on the basis of the availability and cost of 
enriched target materials. In nearly all of the target materials the burnout rate calculated for typical 
irradiation cycles is small, thereby permitting reuse of the residual target materials following 
radiochemical separation of the product isotopes. The calculations presented in Table 3 also take into 
account the use of hydrided assemblies to provide neutron energy moderation for aptimizing the 
production of isotopes that have large cross-sections in the epithermal range. In addition, target self- 
shielding effects were calculated and have been taken into account in the isotope production rates 
presented in Table 3. 
Table 3. Production Rates at 100 MW of 30 FFTF Medical Isotopes 
Using the data from Table 3, an estimate has also been made of the extent to which FFlT could meet the 
projected market demand in year 2005 for several therapeutic medical isotopes. For this purpose, a 
patient population database provided by the Frost and Sullivan market analysis company (Mountain 
View, CA) was used This database provides information on the number of patients in the U.S. that will 
be treated for 26 classes of disease over the coming two decades, and makes conservative estimates of the 
fraction of patients that would receive radioisotope therapy. Using information from ongoing clinical 
trials and consultation with nuclear medicine specialists, estimates were made of the number of curies 
quantities of 17 medical isotopes that would be required to treat the patient population that is expected to 
receive radioisotope therapy. 
Table 4 summarizes the projected U.S. demand in year 2005 for 17 therapeutic isotopes, and the 
FFTF's annual production capability for these isotopes when operating at a power level of 100 MW. The 
year 2005 was selected for this comparison because it represents the fist full year that would return 
to full-scale operations under the current planning schedule. The estimate of the medical isotopes market 
in year 2005 is also expected to be more reliable than a longer-range projection. 
Table 4. FFTF Medical Isotope Production versus U.S. Demand 
Isotope 
AC-227"' 
Cu-64 
Cu-67 
He166 
I- 1 25 
1-131 
Ir-192 
Lu-177 
P-32 
Pd-103 
Re-186 
Sc-47 
Sm-153 
Sn-117m 
Sr-89 
Th-229"' 
W-188"' 
(a) Abbreviations 
LTV; R3: Rapid Radioisotope Retrieval System (24 cc target volume); R3-H: Hydrided R3; Gas Line: Target 
volume is 5000 cc. 
(b) Based on projected patient populations treated with isotopes for 26 classes of disease (Frost and Sullivan medical 
isotope market survey, 1997). 
(c) Based on isotope production rates shown in Table 3 and the number of operating cycles per year shown in this table. 
(d) FFTF will have up to 3 core positions for the production of short-lived isotopes in R3 assemblies and up to 12 core 
positions for producing longer-lived isotopes in LTV assemblies; there will be one gas line. 
(e) Ac-227, Th-229, and W-188 are the generators for the short-lived medical isotopes Ra-223, Ac-225/Bi-213, and Re- 
188, respectively. 
Half-Life 
21.8 years 
12.7 hours 
2.58 days 
1.12 days 
60.1 days 
8.04 days 
73.8 days 
6.68 days 
14.3 days 
17.0 days 
3.78 days 
3.35 days 
1.93 days 
13.6 days 
50.5 days 
7300 years 
69.4 days 
are LTV: 
Target 
vehicle") 
LTV-H 
R3 
R3 
R3-H 
Gas Line 
R3-H 
LTV 
R3-H 
R3 
R3-H 
R3-H 
R3 
R3-H 
R3-H 
LN-H 
LTV-H 
LTV-H 
Long Irradiation 
Irradiation 
Time (days) 
100 
10 
10 
10 
100 
25 
100 
25 
25 
25 
25 
10 
10 
25 
100 
100 
100 
Vehicle 
Cycles 
per 
Year 
3 
25 
25 
25 
3 
10 
3 
10 
10 
10 
10 
25 
25 
10 
3 
3 
3 
(10,000 cc 
No. Assemblies 
to Meet Total 
U.S.  ema and'^) 
0.3 
0.02 
2.8 
1.3 
0.09 
5.4 
0.25 
1.2 
0.09 
0.2 
0.02 
1 .O 
1.5 
0.1 
0.15 
10.4 
0.01 
LIV-H: Hydrided 
Projected U.S. 
Demand in 
2005(b) (Ci) 
2.9E+01 
4.0E+00 
2.6E+02 
5.6E+02 
6.5E+02 
1.4E+04 
2.5E+03 
5.OE+00 
3.8E+01 
2.5E+03 
7.3E+02 
4.7E+02 
1.3E+03 
4.7E+01 
6.3E+01 
8.4E-01 
1.5E42 
total target volume 
FFTF Yearly 
Production Per 
Assembly (~i)") 
1 .OE+02 
2.4E+02 
9.3E+01 
4.3E-142 
7.2E43 
2.6E+03 
1 .OE+04 
4.0E+00 
3.5E+02 
1.2E+04 
3.0E+04 
4.5E+02 
8.8E+02 
4.4E+02 
4.2E+02 
8.1E-02 
1.6E+04 
per assembly); 
From the information presented in Table 4, it is clear that FFTF can supply all, or a large fraction of, 
the projected U.S. requirement for these 17 thexapeutic isotopes in the year 2005. This conclusion is 
based on the favorable comparison shown in Table 4 between the projected market demand and the 
production capacity of FFW. Even for those isotope products that will require more than one core 
assembly to meet the production demand, a sufficient number of R3 and LIV target assemblies can be 
deployed to increase the FFTF's production capacity up to a level that meets the projected demand 
A comparison has also been made of the isotope production capacity of FFTF relative to the High 
Flux Isotope Reactor (HER) at the Oak Ridge National Laboratory, which is currently a major source of 
medical'isotopes produced under the D O W - 7 0  program. This comparison was made on the basis of 
two key factors: (1) the curies of a product isotope that can be produced p a  gram of target material in a 
typical irradiation cycle, and (2) the target volume available in the reactor's core region. These factors 
Table 5. Comparison of Medical Isotope Production by FFTF and HFIR'"' 
Isotope 
Ac-227 
Cd-109 
Cu-64 
Cu-67 
Ho-166 
1-131 
Ir-192 
Mo-99 
0s-194 
P-32 
P-33 
Pd-103 
Pt-195m 
Re-186 
Sc-47 
Se-75 
Sm-145 
Sm-153 
Sr-89 
Th-228 
Th-229 
W-188 
Xe-127 
(a) HFIR 
(b) For consistency with data available for HFIR, the isotope production calculations shown in this table are based on peak 
fluxes rather than volume-average fluxes, and do not include self-shielding corrections. In contrast, the information 
contained in Tables 3 and 4 is based on calculations that used volume-averaged fluxes in the target assemblies and included 
self-shielding corrections. 
(c) Target volumes for the FFTF are based on the use of 3 R3 and 9 LIV assemblies for medical isotope production. 
Target 
Material 
Ra-226 
Cd-108 
Zn-64 
Zn-67 
Ho-165 
Te-130 
Ir-191 
Mo-98 
0s-192 
S-32 
S-33 
Pd-102 
Pt-195 
Re-185 
Ti-47 
Se-74 
Sm-144 
Sm-152 
Sr-88 
Ra-226 
Ra-226 
W-186 
Xe-126 
is the High 
F F ~  
2.53E+00 
6.1 9E+00 
1.56E+00 
6.79E-02 
1.59E+03 
6.61 E+00 
1.26E+02 
7.88E+01 
6.80E+00 
5.90E+00 
1.84E+01 
1.12E+02 
5.77E+00 
3.51 E+03 
1.66E+00 
1.43E+03 
2.00E+O1 
7.33E+03 
6.34E-01 
1.30E+02 
3.70E-02 
5.95E+00 
2.95E+02 
Flux Isotope 
HFIR 
1.52E+00 
5.34E+00 
1.1 8E+00 
4.90E-02 
1.25E+03 
3.59E+01 
5.23E+01 
2.74E+01 
8.00E+00 
4.28E+00 
4.93E+01 
2.95E+02 
4.08E+00 
7.83E+03 
1.09E+00 
6.08E+03 
1.00E+01 
1.91 E+03 
1.76E+00 
9.1 1 E+O 1 
2.00E-02 
4.99E+01 
6.88E+02 
Reactor located 
(FFTFMFIR) 
1.7 
1.2 
1.3 
1.4 
1.3 
0.2 
2.4 
2.9 
0.9 
1.4 
0.4 
0.4 
1.4 
0.4 
1.5 
0.2 
2.0 
3.8 
0.4 
1.4 
1.9 
0.1 
0.4 
at the Oak Ridge 
FFTF 
38500 
77100 
72 
72 
72 
72 
77100 
72 
77100 
72 
77100 
72 
72 
72 
72 
38500 
38500 
72 
38500 
38500 
38500 
38500 
77100 
National 
HFIR 
464 
464 
12.9 
12.9 
12.9 
12.9 
464 
12.9 
464 
12.9 
464 
12.9 
12.9 
12.9 
12.9 
464 
464 
12.9 
464 
464 
464 
464 
464 
Laboratory 
(FFTFIHFIR) 
83.0 
166.2 
5.6 
5.6 
5.6 
5.6 
166.2 
5.6 
166.2 
5.6 
166.2 
5.6 
5.6 
5.6 
5.6 
83.0 
83.0 
5.6 
83.0 
83.0 
83.0 
83.0 
166.2 
in Oak Ridge, 
(Prod. Ratio 
x Vol. Ratio) 
140 
190 
9.5 
7.8 
7.3 
1.1 
400 
. 16.2 
1 40 
7.8 
62 
2.2 
7.8 
2.2 
8.4 
20 
170 
21 
30 
1 20 
150 
9.9 
71 
Tennessee. 
were calculated for isotope targets placed in the high-flu region of the HFIR reactor (the "flux trap"), 
and for isotope production assemblies placed in Rows 4 and 6 of the FlTF's core region. As shown by 
the calculations presented in Table 5 for 23 medical isotopes, the rate of production per gram of target 
mataial is similar in HFIR and FFTF for many of the product isotopes. However, the large core volume 
of the FFW compared to the HFIR flux trap provides a distinct overall production advantage for FITF 
over HFIR for all of the 23 isotopes that were analyzed 
2.4 Organizational Structure of the Radioisotopes Production Program 
2.4.1 Pacific Northwest National Laboratory's Radiochemical Processing Group 
Radiochemical research and development at PNNL are conducted by memks of the Radiochemical 
Processing Group (RPG), which consists of 75 technical and administrative staff located in a 144,000 ft2 
Category I1 nuclear facility - the Radiochemical Processing Laboratory (described in Section 2.5.1 of 
this repart). The RPG, headed by Dr. John LaFemina, is administratively located within the 
Environmental Technology Division (ETD), one of the four major research divisions at PNNL. 
The organizational structure of the ETD and the RPG are illustrated in Figure 5. ' 
B.D. Shipp, GIvmrn 
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Figure 5. Organizational Chart for the PNNL Environmental Technology Division 
The primary missions of the RPG are to create and implement innovative processes for environmental 
cleanup and the beneficial use of radioactive materials. Primary areas of research include (1) the 
development of technologies for the cleanup of hazardous radiological wastes, (2) the processing and 
disposal of nuclear fuels, and (3) the production of medical isotopes. The total business volume of the 
RPG in FY 1999 is projected to be $38M, the majority of which is based on DOE funding from the Office 
of Environmental Management, Defense Programs, the Office of Civilian Radioactive Waste 
Management, and the Office of Nuclear Energy, Science and Technology. 
The RPG's staff is divided into six teams that represent the main technical capabilities of this 
organizational unit: (1) shielded facility operations for work with high levels of radioactive materials, 
(2) radiomaterials performance, (3) physical radiochemistry, (4) separations radiochemistry, 
(5) radioanalytical applications, and (6) isotope production. 
2.4.2 Fast Flux Test Facility 
The current organizational structure of the FFlT is shown in Figure 6. As discussed in Section 2.1 of 
this report, the reactor is currently in a standby mode of operation. Approximately 250 technical and 
administrative staff are involved in maintaining all of the essential operating systems and support senices 
in a functional condition, including the reactor's liquid sodium heat transport system. The operating 
budget for the FlTF in FY 1999 is $NM. 
Plans are being developed for the FFTF's operational and organizational s t r u m  if DOE makes a 
decision to restart the reactor for a future nuclear science and irradiation services mission. For operations 
at a 100-MW power level, a total support staff of 410 FTE is expected to be required. The annual 
baseline operating budget under this condition will be $55M during the first year of full-scale reactor 
operations in FY 2005. 
As part of the 90-day FFTF scoping study that is currently in progress, a business model is being 
developed that will incarparate the organizational and fiscal requirements for support of the wide range of 
products and services to be offered by the reactor. An emphasis is being placed on the development of 
productive partnerships between the federal government and private sector organizations that will benefit 
from the reactor's capabilities. 
2.4.3 Isotope Program Management 
As described in Section 2.4.1, the isotopes program at PNNL is located organizationally within the 
RPG. The Manager of the DOE-spansored Hanford Radioisotopes Program, Dr. Thomas Tenforde, also 
functions as the lead scientist for the RPG's 12-memk Isotope Production Team. In that capacity he has 
line management responsibilities for the staff and facilities involved in the radiochemical processing of 
isotopes for commercial and medical applications. These staff, tog- with a matrixed team of nuclear 
physicists, engineers, radiochemists, and nuclear safety specialists from PNNL and other Hanford 
Fast Flox 
Test Facility 
* 
E.F. Lolka, DImctor 
FFTF Plant 
Deputy Manager 
D.M. Lucofl El- 
Total Wf339 Staff: 251 
Operations 
~ s s u  rance 
J.E. Parker, Manager R.0. Ummennsn, Manager 
Operations 
S.V. Doebler, Menager 
FFTF Transition 
Project Office 
RA. Hulvey. Manager 
Figure 6. Organizational Chart for the Fast Flux Test Facility 
contractor organizations, have functioned since 1997 as a support group for planning the proposed future 
FFTF isotope production mission. In all of these activities, excellent communication channels have been 
maintained between members of the isotopes program and key staff in the DOE Richland Operations 
Office. 
Engineering 
S. Guttenberg, 
Manager 
Technical 
support 
S. W. Scvit, Manager 
2.5 Isotope Production Facilities 
Plant 
Maintenance 
G.J. Boehnke, 
Maneger 
Radiological 
Control 
L.A. Nelsen, Manauer 
2.5.1 Radiochemical Processing Laboratory 
The Radiochemical Processing Laboratory (RPL), which houses the research and development 
activities of the RPG (discussed in Section 2.3. I), is located in the 300 Area of the Hanford Site and is 
designated as Building 325. The RPL contains laboratories and specialized facilities designed for work 
with nonradioactive materials, microgram-to-kilogram quantities of fissionable materials, and up to 
megacurie quantities of other radionuclides. The RPL was built in 1953 and consists of a central area that 


sectioning and processing, metallography, physical properties testing of activated metals, thermal 
processing (including waste vitrification), and radioanalytlcal and preparatory chemistry operations. 
The HLRF contains three large, interconnected hot cells designated as A-Cell, B-Cell, and C-Cell. 
The three cells are each 15 ft  high and 7 ft deep; the A-Cell is 15 ft  wide and the B-Cell and C-Cell are 
each 6 ft  wide. In-cell operations are performed using medium-duty electromechanical manipulators, 
with viewing of the work through leaded-glass, oil-filled windows. Closed-circuit television cameras and 
VCRs have been installed for detailed inspection work within the hot cells. The A-Cell and C-Cell also 
have overhead bridges that contain hoists with a 2200-kg capacity. The hot cells are fully equipped with 
utilities, and have shielded service penetrations at the front wall for insertion of special instrumentation. 
Each hot cell contains several process vessels, which are located below the work deck and range in 
capacity from 4 to 320 liters. Access to each hot cell in the HLRF is provided by a large shielded door 
and a shielded double-door transfer port located in the rear wall of the cell. Cask payloads weighing up to 
2200 kg can be transferred into and out of the hot cells using a bridge crane located in the canyon behind 
the cells. 
The SAL contains six interconnecting hot cells, each of which is 5.5 ft  wide, 5.5 ft  deep, and 9.5 ft  
high. Each hot cell is equipped with a pair of medium-duty manipulators. Turntables built into the rear 
walls of the hot cells provide rapid transfers of radioactive samples into and out of the cells. The SAL hot 
cells are equipped to perform a wide variety of analytical chemistry operations with highly radioactive 
samples. 
As part of the planning activities for a future radioisotope production mission at FFTF, an engineering 
assessment was made of the capabilities of the RPL to support the radiochemical processing requirements 
for a wide variety of irradiated target materials. Figures 9 and 10 illustrate a preliminary design of the 
RPL facilities modifications that could be made to accommodate the preparation and processing of targets 
and isotope products following irradiation at FFTF and transport in shielded casks to the RPL. Transport 
would take place over a distance of - 10 miles on a four-lane highway within the Hanford Site. 
The general features and functions of the RPL laboratories that would be used for processing targets 
irradiated at FFTF have been described in a PNNL report.' In brief, some of the primary features of the 
these laboratories would be as follows: 
1. A cluster of 10 laboratories would be available on the first floor of the RPL; each laboratory would 
contain a small hot cell, a shielded glove box, and a fume hood with interconnecting transfer ports. 
2. A transfer port for receipt of casks containing irradiated targets into the A-Cell of the HLRF would be 
installed, and provision would be made in the C-cell for initial processing of highly radioactive 
targets (e.g., irradiated europium targets containing gadolinium-153 product). 
' L'Medi~al Isotope Production at the Fast Flux Test Facility: A Technical and Economic Assessment." 
Pacific Northwest National Laboratory Rep. No. PNNL-SA-29592, Richland, Washington (1997). 

3. Target preparation and storage areas would be provided in the basement of the RPL, in close 
proximity to facilities for the assembly and welding of radioactive and recycled targets. 
4. A 1500-ft2 laboratory equipped with a radon gas capture system would be available in the RPL 
basement for the processing of radium-226 targets and the product isotopes generated by irradiation 
of these targets at FFTF (all of which generate radon gas as intermediate products in their 
decay chains). 
2.5.2 FFTF 
The FFTF consists of the reactor and several support buildings and equipment arranged around the 
central reactor containment building, as shown in Figures 11 and 12. The reactor is located in a shielded 
cell at the center of the containment building. Heat is removed from the reactor by liquid sodium that is 
circulated through three primary loops, which include the pumps, piping, and intermediate heat 
exchangers. As illustrated in Figure 13, the primary loops are connected to secondary loops consisting of 
pumps, piping, flow meters, and heat exchangers. At full-power operation, the reactor inlet temperature 
of the sodium is 360 OC and the outlet temperature is 527 OC. During a total loss of power, the FFTF is 
designed to shut down automatically and the reactor will continue to be cooled by natural circulation of 
the sodium An emergency power source consisting of batteries will provide essential plant monitoring 
capabilities in the event of a shut down. The reactor also has safety features that can maintain cooling if a 
leak occurs in the liquid sodium heat transport system. These safety features involve the use of elevated 
piping and guard vessels around all of the major components of the reactor core. 
Figure 14 is a cutaway view of the reactor containment building, showing the locations of the primary 
pumps and intermediate heat exchangers. Secondary sodium loops transport the reactor heat from the 
intermediate heat exchangers to the air-cooled tubes of the dump heat exchangers located outside of the 
reactor containment building. 
Another ,major system located in the reactor containment building is the Closed Loop Ex-Vessel 
Handling Machine (CLEM) that is used to install fuel and target assemblies in the reactor and to remove 
them at the end of the irradiation cycle. Figure 15 is a photograph of the CLEM system. 
After completion of an irradiation cycle, an irradiated assembly is transferred by CLEM from the 
reactor to the Interim Examination and ~aintenance (EM) Cell. In the E M  Cell, which is shown in 
Figure 16, the irradiated assembly is washed and dried to remove residual sodium prior to disassembly. 
Following this procedure, irradiated target pins are removed from the assembly using the E M  Cell's 
manipulators, and are then loaded into pin containers for removal from the E M  Cell. The pin container is 
then transferred to an intermediate holding cell using CLEM. A bottom-loading transfer cask, shown in 
Figure 14, is then used to transfer the pin container from the reactor containment building to the cask 
loading station in the Reactor Service Building. At the cask loading station the pin container is loaded 
into an appropriate transportation cask such as the T3 for transfer to radiochemical processing facilities at 
the RPL or other locations. 
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2.5.3 Other Facilities Relevant to the Proposed Future FFTF Isotope Production Mission 
U In planning for a proposed future FFTF isotope production mission, several facilities at the Hanford 
Site in addition to the RPL have been examined as possible locations for the preparation of targets and the 
processing of isotope products. In all cases, these facilities are in good condition and have some desirable 
physical features and equipment that could make them advantageous as locations for the preparation 
andlor processing of FFTF targets. Three of these facilities are briefly described below. 
Building 306E. This facility is located in the 300 Area of the Hanford Site, and has been used to 
fabricate a variety of reactor components, fuel assemblies, and radioisotope target assemblies in the past. 
Some of the equipment and Non-Destructive Examination (NDE) equipment still exist in the building. 
Based on a preliminary engineering evaluation, a conceptual design plan has been developed for the 
utilization of Building 306E for the fabrication of isotope targets and gas tag capsules. Figure 17 shows 
the first floor plan of the building and the areas that would be used to fabricate and test the target pins for 
LIV assemblies and the encapsulated targets for R3 assemblies. The targets would be subjected to NDE 
and placed in secure storage areas within Building 306E before shipment to FFTF. 
Postirradiation Testing Laboratory (PTL). The PTL is located in the 300 Area at the Hanford Site 
and is designated as Building 327. This facility contains 13 hot cells and support laboratories for the 
physical and metallurgical examination of irradiated fuels, fission products, and irradiated structural 
materials. A floor plan of the PTL is shown in Figure 18. The central region of the building contains a 
215 ft. by 32 ft. canyon area, with two overhead bridge cranes that can transport shielded containers or 
heavy equipment weighlng up to 20 tons. This central canyon area contains 10 large hot cells and transfer 
storage areas. All of the hot cells are heavily shielded and fully equipped with viewing windows, 
manipulators, and utilities. One of the hot cells is the Special Environmental Radiometallurgy Facility 
(SERF), which has an inert nitrogen gas atmosphere. The basement of the PTL contains equipment 
storage facilities, hot cell exhaust systems, high-level liquid waste piping, and the building's power and 
utility services. 
Decontamination of the hot cell facilities at the PTL has been underway for two years, and is 
expected to be completed within the next two years. Only a small amount of programmatic work is 
currently being conducted at the PTL, and a study on the long-range utilization of this facility is 
underway. One option that is being explored is the use of part or all of the PTL's facilities by comrlercial 
companies under lease agreements. This alternative may be attractive for establishing long-term business 
relationships with companies interested in the preparation and processing of targets irradiated at FFTF. 
Maintenance and Storage Facility (MASF). The MASF is a multi-purpose service center which 
supports the specialized maintenance and storage requirements of the FFTF. The building is located 
-500 ft. north of FFTF, and is within the security perimeter of the 400 Area on the Hanford Site. The 
MASF provides the capability for sodium film removal, decontamination, repair, and storage of non-fuel 
components and hardware for the FFTF. A floor plan for the main building is shown in Figure 19. The 
MASF complex consists of the main building and a two-story service wing. 
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Figure 19. Floor Plan of the FFI'F Maintenance and Storage Facility (MASF) 
The main building of the MASF facility contains a 28,000 ft2 area that is serviced by a 60-ton 
overhead bridge crane and a 10-ton auxiliary hoist. One half of this area is a high-bay section that is also 
serviced by a 200-ton overhead crane and a 25-ton auxiliary hoist. This section of the building has a 
height of 105 ft. and contains floor space for repairs and maintenance of large equipment. It also has 
below-grade shielded hot cells far sodium cleaning and equipment maintenance activities. The other half 
of the MASF's main building is a low-bay area with a height of 49 ft. and a 10-ton overhead hoist that is 
used to handle equipment during transport to and from the decontamination areas in MASF. 
A special feature of the MASF is a large shielded enclosure that contains two shielded 
decontamination rooms (denoted as Decon I and 11). These areas can be used for both remote and 
hands-on cleaning of small equipment items and tools that are contaminated with radioactive material. 
The Decon I area contains viewing windows and manipulators far remote operations and has a 5-ton 
overhead hoist. 
2.5.4 Capital Investment Requirements 
As part of the planning activities for a future FFTF nuclear science and irradiation services mission, 
an estimate has been prepared of the costs associated with restarting the reactor for steady-state operations 
at a 100 MW power level. This estimate, expressed in FY 1999 dollars, is $229M. The capital 
expenditures are distributed over a four-year period from FY 2001 - FY 2004, and include funds far 
(1) recovering systems that were shut down prior to the standby decision in late 1993, (2) equipment and 
instrumentation upgrades, (3) fabrication of R3 vehicles far retrieval of short-lived isotopes, 
(4) modification of hot cells and support laboratories for target processing operations, and (5) staff 
increases and training. Once restarted, the estimated annual cost of FFTF operations is $55M. A more 
detailed description of the schedule and costs for FFTF restart are contained in a document submitted to 
DOE in March, 1999.~ 
2.6 Isotope Production Costs, Pricing, and Sales Record 
2.6.1 Activity-Based Costing and Isotope Pricing 
Approximately four to five months prior to the beginning of a new fiscal year, the PNNL isotopes 
program office prepares a budgeted operations statement with supporting schedules and costlprice 
analyses for each isotope product and related services. This statement contains detailed estimates of labor 
and supply costs for each element of work involved in the production, packaging, sales and distribution 
of isotope products. Estimates of labor and supply costs associated with process development projects are 
also included in the budgeted operations statement. An activity-based costing process is used, with the 
elements of work defined in a four-level work breakdown structure (WBS). As an example of this 
process, Table 6 shows the dements of the first three WBS levels for activities described in the FY 1999 
budgeted operations statement prepared by PNNL. 
Following a review of the annual operations statement by staff at DOEINE-70 and final decisions on 
the fiscal year budget for the isotopes program, discussions are held between DOE and the PNNL 
manager of the Hanford Radioisotopes Program. Based on these discussions, any necessary 
modifications are made in the planned activities and associated costs. Upon receipt of formal guidance 
from DOE on funded activities during the coming fiscal year, the PNNL manager of the Hanford 
Radioisotopes Program prepares a detailed Project Management Plan (PMP) for approval by the DOE 
Richland Operations Office. Significant deviations from schedule or cost in any element of work 
described in the PMP are addressed by a formal change control process involving DOE review and, if 
necessary, budget adjustments that are subject to approval by DOE/NE-70. Revenues from isotope sales 
and expenses associated with a l l  program activities are summarized in monthly, quarterly, and annual 
reports submitted to DOE. 
The use of activity-based costing has been very beneficial in tracking expenses associated with the 
production, packaging, distribution and sales of medical isotopes produced by PNNL. During the period 
from 1996 to 1998 in which the revenue from sales of PNNL's yttrium-90 product increased 14-fold, 
increases also occurred in the costs of production, packaging and distribution of this product which could 
be closely monitored by using the activity-based costing method. An example of the type of activity 
flowchart developed by PNNL is shown in Figure 20 for work related to the packaging and shipping of 
yttrium-90 to medical customers. Using the four-level WBS approach, costs were closely estimated for 
each element of work shown in the flowchart. These costs. are summarized in Table 7. A flowchart and 
8 
"Capabilities and Economic Assessment of the Use of the Fast Flux Test Facility for Isotope Production 
and Research." Predecisional draft report for the DOE Office of Nuclear Energy, Science, and 
Technology (March 18,1999). 
activity-based cost analysis were also prepared for the radiochemical tasks associated with extraction of 
yttrium-90 from strontium-90 generators and the subsequent dispensing of the yttrium-90 product into 
customer vials. By using this activity-based approach, it was possible to anticipate increases in the 
expense associated with providing yttrium-90 to medical customers as a function of the number of vials 
prepared and the nwnber of packages shipped to customers on a weekly basis. Accurate projections can 
also be made by this method of the monthly revenue versus expense profile, as well as the "economy of 
scale" achieved by serving a rapidly expanding market. 
Table 6. Level 3 Work Breakdown Structure Outline 





